The global phenylketonuria (PKU) therapeutics market is projected to grow significantly, with its valuation increasing from US$ 1 billion in 2023 to an anticipated US$ 2.28 billion by 2033, reflecting a robust CAGR of 8.6% during the forecast period. This marks a substantial acceleration compared to the 5.2% CAGR recorded during the historical period of 2018 to 2022.
Phenylketonuria is a rare genetic disorder that requires effective therapeutic interventions to manage symptoms and prevent complications. The market growth is fueled by increasing awareness of PKU, advancements in treatment approaches, and greater accessibility to innovative therapeutics.
Market Growth Drivers:
- Increasing Awareness: Rising awareness about PKU and its management is leading to earlier diagnosis and treatment.
- Advancements in Therapies: Innovative therapies, including enzyme substitution and gene therapies, are improving patient outcomes.
- Supportive Regulations: Favorable policies and funding for rare disease treatments are accelerating drug development and availability.
- Growing Prevalence: A rise in PKU diagnoses worldwide is driving demand for effective therapeutics.
A Full Report Overview – https://www.futuremarketinsights.com/reports/phenylketonuria-therapeutics-market
Key Takeaways:
- The phenylketonuria therapeutics market is expected to expand at a CAGR of 8.6% from 2023 to 2033, reaching US$ 2.28 billion by the end of the forecast period.
- Enhanced awareness and advanced therapeutic options are primary growth accelerators.
- Increasing investments in rare disease drug development are fueling innovation in PKU treatment.
- The market’s growth trajectory demonstrates significant momentum compared to the historical period, highlighting its expanding importance in healthcare.
Market Drivers
- Increasing Awareness: Growing awareness about phenylketonuria and its management among healthcare professionals and patients is driving demand for effective therapeutics.
- Technological Advancements: Innovations in treatment options, including new therapies and dietary management solutions, are enhancing patient outcomes and expanding market potential.
- Growing Demand for Early Diagnosis: The rise in newborn screening programs and genetic testing has led to earlier diagnosis of PKU, increasing the need for timely therapeutic interventions.
- Rising Prevalence of PKU: The incidence of PKU is estimated at approximately one in every 10,000 to 15,000 newborns, contributing to a higher demand for effective treatments.
- Supportive Government Policies: Many governments are implementing policies that promote screening and treatment for rare metabolic disorders like PKU, further propelling market growth.
Regional Insights
- North America is expected to dominate the market due to high rates of diagnosis and advanced healthcare infrastructure.
- The market in East and South Asia is anticipated to grow significantly, driven by increasing healthcare investments and awareness campaigns.
Market Competition
Key players in the market include companies such as Competition Deep Dive, Cigna, BioMarin Pharmaceuticals, Codexis, Inc., Erytech Pharma, SOM Innovation Biotech SL, Synthetic Biologics, Inc., Retrophin, Inc., Danone, Censa Pharmaceuticals, Homology Medicines, Inc., along with healthcare providers and technology companies among other global players.
- In January 2023, Jnana Therapeutics was granted clearance by the FDA for its Investigational New Drug (IND) application for JNT-517, a drug being developed to treat phenylketonuria (PKU), a condition that is difficult to treat. The biotechnology company is using its advanced chemoproteomics platform to discover drugs for challenging targets. The Phase 1 program of JNT-517 is currently underway in healthy volunteers in Australia, and will expand to include clinical sites in the USA The Phase 1b sub-study will evaluate the drug’s effectiveness in individuals with PKU, with the potential to demonstrate clinical proof of concept that supports a subsequent registrational program.
Key Companies Profiled
- The Cigna Group
- BioMarin Pharmaceutical Inc.
- Codexis Inc.
- Erytech Pharma S.A
- SOM Innovation Biotech S.A
- Synthetic Biologics, Inc. (Theriva)
- Retrophin Inc. (Travere Therapeutics)
- Danone S.A.
- Censa Pharmaceuticals (PTC Therapeutics)
- Homology Medicines Inc.
Key Segments Profiled in the Phenylketonuria Therapeutics Industry Survey
Drug Type:
- Kuvan
- Playnziq
Route of Administration:
- Oral
- Parenteral
- Intravenous
- Subcutaneous
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:
HPV Testing and Pap Test Market
Dental Simulator Market
Helicobacter Pylori Non-Invasive Testing Market
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube